Landmark trials of medicine, told in a single sentence.
61 artificial intelligence trials in 11 topics.
Topics in artificial intelligence
AI-enabled electrocardiography
AI-ECG screening for low ejection fraction, cardiomyopathy, cirrhosis and potassium, mortality and STEMI alerts, AF screening, an AI stethoscope and ambulatory ECG reporting.Computer-aided detection in endoscopy
Real-time CADe for adenoma detection and miss rate, the advanced-neoplasia and community-practice negatives, AI optical diagnosis and the deskilling signal.AI in echocardiography & cardiac imaging
AI versus sonographer ejection fraction, AI-augmented stress echo, opportunistic calcium scoring, machine-learning CT-FFR, AI-guided AF ablation and device telemonitoring.Large language models in clinical decision-making
GPT-4 and purpose-built LLMs for diagnostic and management reasoning, antimicrobial prescribing, specialist referral and primary care, tested against physicians.AI in mammography screening
MASAI's randomised AI-supported screen reading, paired-reader and nationwide implementation studies, and AI triage of tomosynthesis.Deterioration & sepsis alerts
Machine-learning and electronic early-warning systems on hospital wards: CONCERN, SCREEN, the Kaiser Advance Alert Monitor and TREWS.Intraoperative hypotension prediction
The Hypotension Prediction Index trials: HYPE and its replications in non-cardiac, cardiac and abdominal surgery.Patient-facing AI
AI insulin dosing, autonomous diabetic retinopathy screening, AI lifestyle coaching and a generative-AI therapy chatbot.Prognostic nudges & palliative care
Machine-learning mortality estimates paired with behavioural nudges to prompt serious illness conversations and palliative referral.AI triage in radiology
AI prioritisation of chest radiographs in the lung-cancer pathway, AI-read OCT for macular oedema and generative low-dose angiography.Ambient AI documentation
Ambient AI scribes and AI-drafted patient messages, measured on time in notes, burnout and well-being.
In 17,187 patients with suspected acute myocardial infarction, aspirin plus intravenous streptokinase reduced 5-week vascular mortality compared with placebo.